WHAT IS CLAIMED IS:

1. A compound of the formula I:



I

wherein:

W is selected from the group consisting of:

(1) tetrazolyl,
(2) CO_2H,
(3) $NHSO_2C_{1-6}$alkyl, and
(4) $CONHCO\text{-}C_{1-6}$alkyl;

X is selected from the group consisting of:

(1) -O-,
(2) -S-, and
(3) -NH-,
(4) $-N(C_{1-6}alkyl)-$,
(5) a bond;

Y is selected from the group consisting of:

(1) -O-, and
(2) -S-;

R1 is selected from the group consisting of:

(1) C_{1-6}alkyl, which is unsubstituted or substituted with a substituent selected from:
   (a) halogen,
   (b) hydroxyl, and
   (c) phenyl, wherein the phenyl is unsubstituted or substituted with 1-5 substituents independently selected from halogen, cyano, CF_3, hydroxyl, C_{1-6}alkyl, and OC_{1-6}alkyl,

(2) C_{3-7}cycloalkyl, which is unsubstituted or substituted with halogen, hydroxyl or phenyl, and

(3) phenyl, wherein the phenyl is unsubstituted or substituted with 1-5 substituents independently selected from halogen, hydroxyl, cyano, CF_3, C_{1-6}alkyl, and OC_{1-6}alkyl, wherein the C_{1-6}alkyl and OC_{1-6}alkyl are linear or branched and optionally substituted with 1-5 halogen;

R^2 is selected from the group consisting of:

(1) hydroxyl,

(2) halogen,

(3) OC_{1-6}alkyl, and

(4) C_{1-6}alkyl, which is unsubstituted or substituted with halogen, hydroxyl or phenyl;

R^3 is selected from the group consisting of:

(1) C_{1-6}alkyl, which is unsubstituted or substituted with halogen, hydroxyl or phenyl, and

(2) halogen, and

(3) hydrogen;

R^4 is selected from the group consisting of:

(1) hydrogen,

(2) halogen, and

(3) C_{1-6}alkyl;

m is an integer selected from 0, 1, 2 and 3;
n is an integer selected from 0, 1, 2, 3, 4, 5 and 6;
and pharmaceutically acceptable salts thereof and individual diastereomers thereof.

2. The compound of Claim 1 wherein W is selected from tetrazolyl and CO_2H.

3. The compound of Claim 1 wherein X is -O-.

4. The compound of Claim 1 wherein Y is -O-.

5. The compound of Claim 1 wherein X is a bond and Y is -O-.

6. The compound of Claim 1 wherein R^1 is selected from

(1) C_{1-6}alkyl, and
(2) C_{5-6}cycloalkyl.

7. The compound of Claim 6 wherein R^1 is selected from

(1) CH_3,
(2) $CH(CH_3)2$,
(3) CH_2CH_3,
(4) $CH_2CH_2CH_3$,
(5) cyclopentyl,
(6) CH_2-cyclopentyl,
(7) phenyl, and
(8) CH_2phenyl.

8. The compound of Claim 1 wherein R^2 is selected from hydroxyl and chloro.

9. The compound of Claim 1 wherein R^3 is selected from

(1) C_{1-6}alkyl,
(2) CH_3,
(3) CH_2CH_3,
(4) $CH_2CH_2CH_3$, and
(5) chloro.

10. The compound of Claim 1 wherein R^4 is hydrogen.

11. The compound of Claim 1 wherein m is 0 or 1.

12. The compound of Claim 1 wherein n is selected from 1, 2, 3 or 4.

13. A compound which is selected from the group consisting of:





















5











5











5











5











and pharmaceutically acceptable salts thereof.

14. A pharmaceutical composition which comprises an inert carrier and a compound of Claim 1.

15. A method for potentiation of metabotorpic glutamate receptor activity in a mammal which comprises the administration of an effective amount of the compound of Claim 1.

16. A method for the manufacture of a medicament for potentiation of metabotorpic glutamate receptor activity in a mammal comprising combining the compound of Claim 1 with a pharmaceutical carrier or diluent.

17. A method for treating a neurological and psychiatric disorders associated with glutamate dysfunction in a mammalian patient in need of such which comprises administering to the patient a therapeutically effective amount of a compound of Claim 1.

18. A method for treating anxiety in a mammalian patient in need of such which comprises administering to the patient a therapeutically effective amount of a compound of Claim 1.

19. A method for treating depression in a mammalian patient in need of such which comprises administering to the patient a therapeutically effective amount of a compound of Claim 1.

20. A method for treating migraine in a mammalian patient in need of such which comprises administering to the patient a therapeutically effective amount of a compound of Claim 1.

21. A method for treating schizophrenia in a mammalian patient in need of such which comprises administering to the patient a therapeutically effective amount of a compound of Claim 1.

22. A method for treating epilepsy in a mammalian patient in need of such which comprises administering to the patient a therapeutically effective amount of a compound of Claim 1.